<<snip>>
these are the first data documenting improvement in clinical outcome in
patients with Myelodysplastic Syndrome who received Iron Chelation
Therapy
<<snip>>
DGDispatch
Iron Chelation for Myelodysplastic Syndromes Improves Survival Rate:
Presented at ASH
By Bruce Sylvester
ORLANDO, FL -- December 12, 2006 -- Patients with myelodysplastic
syndromes (MDS) who are treated with iron chelation therapy (ICT)
achieved a significant improvement in overall survival after 4 years on
this therapy, according to research reported here at the 48th Annual
Meeting of the American Society of Hematology (ASH).
"To our knowledge these are the first data documenting improvement in
clinical outcome in patients with MDS who received ICT," said lead
investigator and presenter Heather Leitch, MD, PhD, clinical assistant
professor, University of British Columbia, Vancouver, British Columbia,
Canada.
Dr. Leitch and colleagues conducted a retrospective review of 178
patients who had a bone marrow diagnosis of MDS and were seen at St.
Paul s Hospital in Vancouver, Canada, from January 1981 to April 2006.
The researchers collected clinical data from the practice database, the
Iron Chelation Program of British Columbia database, and by chart
review.
They applied the International Prognostic Scoring System (IPSS) and
predicted the course of MDS in 44 patients classified as low risk, 55
classified as intermediate-1 risk, 17 intermediate-2 risk patients, and
17 at high risk. They also assessed the data for elevated levels of
ferritin -- an iron-carrying protein -- and clinical evidence of iron
overload.
At a media briefing on December 11th, Dr. Leitch presented results for
18 subjects with low or intermediate-1 risk who were eligible for ICT
due to elevated ferritin levels (13 patients), clinical and biochemical
evidence of iron overload (3 patients), and number of transfusions
received (2 patients). These subjects were treated with a chelating
agent, desferroxamine (0.5-3 g), through subcutaneous infusion over 12
hours, 5 days per week. The median duration of treatment was 15 months.
When compared with non-ICT patients, patients who received ICT had
higher initial median ferritin levels (4,215 vs 1,647 mcg/L) and
significantly lower median post-ICT ferritin levels (2,659 mcg/L vs
3,188 mcg/L),
In non-ICT patients who died during the study period (n=71), documented
causes of death were acute leukemia (22 patients), MDS-related (21
patients), infection/sepsis (18 patients), and non-MDS-related (10
patients). The 3 deaths among ICT patients were due to AML, MDS
complications, and iron overload.
Median overall survival for all subjects was 36 months. Median overall
survival was more than 160 months in patients with low or
intermediate-1 IPSS receiving ICT and 40.1 months in non-ICT patients.
Four-year survival among patients who received ICT was 80% and 44%
among non-ICT patients, the authors noted.
[Presentation title: Improved Survival in Patients with Myelodysplastic
Syndrome (MDS) Receiving Iron Chelation Therapy. Abstract 249]
Privacy Policy | All contents Copyright© 2006 P\S\L Group. All rights
reserved.
Who loves ya.
Tom
Jesus Was A Vegetarian!
http://jesuswasavegetarian.7h.com
Man Is A Herbivore!
http://tinyurl.com/a3cc3
DEAD PEOPLE WALKING
http://tinyurl.com/zk9fk
Iron Chelation for Myelodysplastic Syndromes 
Linear Mode
